FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients With Right Heart Failure
June 1, 2020—Abiomed announced that the FDA has issued an emergency use authorization (EUA) for the company’s Impella RP to include patients with COVID-19–related right heart failure or decompensation, including pulmonary embolism (PE).
FDA Approves AstraZeneca’s Brilinta to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients With CAD
June 1, 2020—AstraZeneca announced FDA approval for Brilinta (ticagrelor) to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).
Analysis of LEADERS FREE Supports Similar PCI Treatment in Women as in Men With High Bleeding Risk
May 29, 2020—The American College of Cardiology announced a recently published study that demonstrated that women with high bleeding risk should not be denied the benefits of percutaneous coronary intervention (PCI) when indicated and that bleeding avoidance strategies should be uniformly adopted for all patients, especially in women.
SCAI Survey Finds That Americans Are Avoiding Treatment for Heart Attack and Stroke Because of COVID-19 Risk
May 29, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that findings from a newly released national survey confirm a growing concern among doctors and hospitals that people are more afraid of contracting COVID-19 by going to the hospital than seeking care for serious medical emergencies like heart attack or stroke.
SCAI Bestows Highest Designation on Leading Interventional Cardiologists
May 28, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of its Master Interventionalists of SCAI (MSCAI) designations during the SCAI 2020 Scientific Sessions Virtual Conference MSCAI recognition ceremony on May 16.
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts
May 28, 2020—Sahajanand Medical Technologies Pvt Ltd (SMT), a global medical device company based in India, announced its entry into the structural heart segment with the acquisition of Vascular Concepts, which is also headquartered in India.